ATE527356T1 - Replikationskompetente viren für genabschaltung von virusinaktivierung faktor - Google Patents

Replikationskompetente viren für genabschaltung von virusinaktivierung faktor

Info

Publication number
ATE527356T1
ATE527356T1 AT05732404T AT05732404T ATE527356T1 AT E527356 T1 ATE527356 T1 AT E527356T1 AT 05732404 T AT05732404 T AT 05732404T AT 05732404 T AT05732404 T AT 05732404T AT E527356 T1 ATE527356 T1 AT E527356T1
Authority
AT
Austria
Prior art keywords
replication competent
target cells
virus inactivation
virus
competent viruses
Prior art date
Application number
AT05732404T
Other languages
English (en)
Inventor
Jan Carette
Beusechem Victor Van
Original Assignee
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg filed Critical Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg
Application granted granted Critical
Publication of ATE527356T1 publication Critical patent/ATE527356T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05732404T 2004-04-15 2005-04-15 Replikationskompetente viren für genabschaltung von virusinaktivierung faktor ATE527356T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076154A EP1586654A1 (de) 2004-04-15 2004-04-15 Replikationskompetente Viren für Genabschaltung von Virusinaktivierungsfaktor
PCT/EP2005/004152 WO2005100576A2 (en) 2004-04-15 2005-04-15 Replication competent viruses capable of silencing virus inhibitory factor expression

Publications (1)

Publication Number Publication Date
ATE527356T1 true ATE527356T1 (de) 2011-10-15

Family

ID=34928159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732404T ATE527356T1 (de) 2004-04-15 2005-04-15 Replikationskompetente viren für genabschaltung von virusinaktivierung faktor

Country Status (11)

Country Link
US (1) US8318149B2 (de)
EP (2) EP1586654A1 (de)
JP (1) JP5008552B2 (de)
CN (1) CN1984996B (de)
AT (1) ATE527356T1 (de)
AU (1) AU2005233302B2 (de)
CA (1) CA2562830A1 (de)
DK (1) DK1749097T3 (de)
ES (1) ES2375061T3 (de)
NZ (1) NZ550855A (de)
WO (1) WO2005100576A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1586654A1 (de) 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replikationskompetente Viren für Genabschaltung von Virusinaktivierungsfaktor
US20110206639A1 (en) * 2004-04-15 2011-08-25 Christie Vermeulen Replication competent viruses capable of silencing virus inhibitory factor expression
CN103122360A (zh) * 2006-02-28 2013-05-29 瓦克萨特公司 嵌合腺病毒载体
BRPI0817356A2 (pt) 2007-11-07 2014-10-07 Du Pont "planta, métodos para aumentar a tolerância ao estresse de nitrogênio em uma planta, de avaliar a tolerância ao estresse de nitrogênio em uma planta, para determinar uma alteração de uma característica agronômica em uma planta e polinucleotídeo isolado"
EP2282776A4 (de) * 2008-04-11 2011-11-09 Lsip Llc Apoptose-induzierendes mittel
US8685937B2 (en) 2008-08-09 2014-04-01 University Of Iowa Research Foundation Nucleic acid aptamers
US20100183558A1 (en) * 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2012047109A2 (en) 2010-10-08 2012-04-12 Orca Therapeutics B.V. Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death
WO2017070113A1 (en) * 2015-10-19 2017-04-27 The United States of America, as represented by the Secretary, Department of Health and Human Sevices Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613750B2 (en) * 1998-03-19 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Method of inhibiting cell proliferation using an anti-oncogene protein
US20020173026A1 (en) * 2001-03-15 2002-11-21 Myriad Genetics, Incorporated Survivin-interacting proteins and use thereof
US6509162B1 (en) * 2000-02-29 2003-01-21 Yale University Methods for selectively modulating survivin apoptosis pathways
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US7655787B2 (en) * 2000-08-23 2010-02-02 Purdue Research Foundation pRNA chimera
US20030203372A1 (en) * 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US20030157030A1 (en) * 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
EP1327688A1 (de) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviren mit erhöhter Lysisfähigkeit
EP1516055A4 (de) * 2002-01-24 2007-08-08 Scripps Research Inst Faserschaftmodifikationen für effizientes zielen
EP1496979A4 (de) * 2002-03-22 2007-10-31 Univ Texas Protamin-adenovirale vektor-komplexe und anwendungsverfahren
AU2003219432B2 (en) * 2002-03-27 2010-04-01 Pharmascience Inc. Antisense IAP nucleobase oligomers and uses thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
EP1439227A1 (de) * 2003-01-15 2004-07-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts HPV-E6-spezifische siRNAs zur Behandlung von HPV-gebundene Tumoren
WO2005005983A1 (ja) * 2003-07-14 2005-01-20 Japan Science And Technology Agency 子宮内膜症関連疾患の診断方法
EP1586654A1 (de) 2004-04-15 2005-10-19 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Replikationskompetente Viren für Genabschaltung von Virusinaktivierungsfaktor

Also Published As

Publication number Publication date
CN1984996A (zh) 2007-06-20
NZ550855A (en) 2010-03-26
US8318149B2 (en) 2012-11-27
WO2005100576A2 (en) 2005-10-27
AU2005233302B2 (en) 2010-07-15
JP5008552B2 (ja) 2012-08-22
CA2562830A1 (en) 2005-10-27
CN1984996B (zh) 2012-09-05
US20070122385A1 (en) 2007-05-31
EP1586654A1 (de) 2005-10-19
AU2005233302A1 (en) 2005-10-27
JP2007532122A (ja) 2007-11-15
ES2375061T3 (es) 2012-02-24
DK1749097T3 (da) 2012-01-30
WO2005100576A3 (en) 2006-04-13
EP1749097A2 (de) 2007-02-07
EP1749097B1 (de) 2011-10-05

Similar Documents

Publication Publication Date Title
ATE552344T1 (de) Viren mit erhöhter lytischer kraft
Sweeney et al. A distinct class of internal ribosomal entry site in members of the Kobuvirus and proposed Salivirus and Paraturdivirus genera of the Picornaviridae
WO2007097820A3 (en) Viral gene products and methods for vaccination to prevent viral associated diseases
DE602004029608D1 (de) Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
WO2005044992A3 (en) Fusion initiation region in rna virus envelope proteins
ATE527356T1 (de) Replikationskompetente viren für genabschaltung von virusinaktivierung faktor
EP2284268A3 (de) Konservierte HBV- und HCV-Sequenzen zur Genausschaltung
EP2527445A3 (de) Behandlung und Prävention von Grippe
JP2008515450A5 (de)
AU2021288648A8 (en) Conjugate of double-stranded siRNA analogue
Arhab et al. Horizontal gene transfer as a mechanism for the promiscuous acquisition of distinct classes of IRES by avian caliciviruses
Pluskota-Karwatka et al. Reducing SARS-CoV-2 pathological protein activity with small molecules
WO2011133040A3 (en) Replication-competent adenoviruses
WO2006120230A3 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
Fernández et al. Evolutionary conserved motifs constrain the RNA structure organization of picornavirus IRES
ATE507293T1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
Sultana et al. Insights into the roles of histone chaperones in nucleosome assembly and disassembly in virus infection
Jalalirad et al. Dominant role of the 5′ TAR bulge in dimerization of HIV-1 genomic RNA, but no evidence of TAR–TAR kissing during in vivo virus assembly
WO2006038129A3 (en) Hepatitis c virus replication system
Lin et al. Structural and functional analysis of the cis-acting elements required for plus-strand RNA synthesis of Bamboo mosaic virus
Alnaji et al. Recombination in enteroviruses is a ubiquitous event independent of sequence homology and RNA structure
JP2005528912A5 (de)
Manzourolajdad et al. Novel polybasic cleavage site in SARS-CoV-2 genome is likely to induce a major change in the RNA secondary structure
WO2007019532A3 (en) Peptide aptamers that bind to the rep proteins of ssdna viruses
Steger et al. Viroid structure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1749097

Country of ref document: EP